Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	76
Overall Study	STARTED	Ontamalimab 25 mg	153
Overall Study	STARTED	Ontamalimab 75 mg	151
Overall Study	Treated	Placebo	76
Overall Study	Treated	Ontamalimab 25 mg	151
Overall Study	Treated	Ontamalimab 75 mg	151
Overall Study	COMPLETED	Placebo	66
Overall Study	COMPLETED	Ontamalimab 25 mg	136
Overall Study	COMPLETED	Ontamalimab 75 mg	138
Overall Study	NOT COMPLETED	Placebo	10
Overall Study	NOT COMPLETED	Ontamalimab 25 mg	17
Overall Study	NOT COMPLETED	Ontamalimab 75 mg	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03259334/flow